NO20085270L - Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni - Google Patents

Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni

Info

Publication number
NO20085270L
NO20085270L NO20085270A NO20085270A NO20085270L NO 20085270 L NO20085270 L NO 20085270L NO 20085270 A NO20085270 A NO 20085270A NO 20085270 A NO20085270 A NO 20085270A NO 20085270 L NO20085270 L NO 20085270L
Authority
NO
Norway
Prior art keywords
schizophrenia
alzheimer
disease
effective
receptor agonists
Prior art date
Application number
NO20085270A
Other languages
English (en)
Norwegian (no)
Inventor
Yun-Xing Cheng
Miroslaw Tomaszewski
Mehrnaz Pourashraf
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20085270L publication Critical patent/NO20085270L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20085270A 2006-06-09 2008-12-16 Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni NO20085270L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81220906P 2006-06-09 2006-06-09
PCT/SE2007/000554 WO2007142583A1 (en) 2006-06-09 2007-06-08 Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia.

Publications (1)

Publication Number Publication Date
NO20085270L true NO20085270L (no) 2009-01-07

Family

ID=38801727

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085270A NO20085270L (no) 2006-06-09 2008-12-16 Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni

Country Status (18)

Country Link
US (1) US7956069B2 (cg-RX-API-DMAC7.html)
EP (1) EP2035411A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009539831A (cg-RX-API-DMAC7.html)
KR (1) KR20090018210A (cg-RX-API-DMAC7.html)
CN (1) CN101501025A (cg-RX-API-DMAC7.html)
AR (1) AR061305A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007256012A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712331A2 (cg-RX-API-DMAC7.html)
CA (1) CA2654138A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088966A (cg-RX-API-DMAC7.html)
IL (1) IL195431A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008015136A (cg-RX-API-DMAC7.html)
NO (1) NO20085270L (cg-RX-API-DMAC7.html)
RU (1) RU2008147542A (cg-RX-API-DMAC7.html)
SA (1) SA07280303B1 (cg-RX-API-DMAC7.html)
TW (1) TW200813018A (cg-RX-API-DMAC7.html)
UY (1) UY30397A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007142583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US20090221567A1 (en) * 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
US20120088791A1 (en) * 2009-02-19 2012-04-12 Vanderbilt University Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
KR20130101040A (ko) * 2010-09-03 2013-09-12 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 억제제로서의 다이-아제티디닐 다이아미드
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EP3774746A1 (en) * 2018-04-06 2021-02-17 Aquinox Pharmaceuticals (Canada) Inc. Indene derivatives useful in treating pain and inflammation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1995002405A1 (en) 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
AU701127B2 (en) * 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
WO1997016192A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6344449B1 (en) 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO1999032481A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
ES2223588T3 (es) * 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
BRPI0113286B8 (pt) 2000-08-14 2021-05-25 Johnson & Johnson pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
MXPA03009600A (es) 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
DE60228072D1 (de) * 2001-04-18 2008-09-18 Euro Celtique Sa Benzimidazolon-verbindungen
US7164024B2 (en) 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
TWI310034B (en) * 2001-10-02 2009-05-21 Acadia Pharmaceuticais Inc Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
AR040405A1 (es) 2002-04-18 2005-04-06 Schering Corp Derivados de bencimidazol utiles como antagonistas de histamina h3
AU2003245565B2 (en) * 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
MXPA06007054A (es) 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
JP2008501031A (ja) 2004-05-28 2008-01-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド ムスカリン受容体のモジュレーター
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006037052A2 (en) 2004-09-27 2006-04-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Modulating mxa expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US20090221567A1 (en) 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
US20090221642A1 (en) 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300

Also Published As

Publication number Publication date
US7956069B2 (en) 2011-06-07
US20070287695A1 (en) 2007-12-13
RU2008147542A (ru) 2010-07-20
TW200813018A (en) 2008-03-16
CN101501025A (zh) 2009-08-05
AR061305A1 (es) 2008-08-20
AU2007256012A1 (en) 2007-12-13
UY30397A1 (es) 2008-01-31
SA07280303B1 (ar) 2011-02-23
ECSP088966A (es) 2009-01-30
EP2035411A1 (en) 2009-03-18
WO2007142583A1 (en) 2007-12-13
IL195431A0 (en) 2009-08-03
MX2008015136A (es) 2008-12-10
JP2009539831A (ja) 2009-11-19
BRPI0712331A2 (pt) 2012-04-03
KR20090018210A (ko) 2009-02-19
CA2654138A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
NO20085270L (no) Muscarin reseptoragonister som er effektive i behandling av smerte. Alzheimers sykdom og schizofreni
IL195427A0 (en) Muscarinic receptor agonists that are effective in the treatment of pain, alzheimers disease and schizophrenia
ZA200808825B (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
EP1928850A4 (en) MEANS FOR PREVENTING AND TREATING DISEASES WITH RYR RECEPTOR MODULATION
EP1933714A4 (en) SYSTEMS, COMPOSITIONS AND METHODS FOR LOCAL PRESENTATION AND TREATMENT OF PAIN
BRPI0907162A2 (pt) Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
ES2764480T8 (es) Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
PL1965816T3 (pl) Kompozycje farmaceutyczne i sposoby leczenia lub zapobiegania chorobom związanym ze szczawianami
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
EP1854415A4 (en) SURGICAL TREATMENT DEVICE
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
EP1761266A4 (en) COMPOUNDS, FORMULATIONS AND METHOD FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY SKIN DISEASES
EP2061314A4 (en) CONNECTIONS TO IMPROVE LEARNING AND MEMORY
BRPI0718041A2 (pt) Antagonista do receptor da angiotensina ii para prevenção ou tratamento de doenças sistêmicas em gatos
EP2005174A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEURODEEGENERATIVE DISEASES AND MORBUS ALZHEIMER AND IMPROVING NORMAL MEMORY
ZA201002016B (en) 3-substituted 1,2,4-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
HUE065668T2 (hu) Delmopinollal bevont, állatoknak való rágóka halitózis megelõzésében vagy kezelésében történõ alkalmazásra
FI20095661L (fi) Toimijan henkilöllisyyden varmennus
DE602006009764D1 (de) Terphenylderivate zur Alzheimerbehandlung
EP2264062A4 (en) Beta-sheet-inhibiting peptides for the prevention and / or treatment of Alzheimer's disease
EP2160475A4 (en) MARKERS AND METHOD FOR EVALUATING AND TREATING CROHN'S DISEASE AND ASSOCIATED DISORDERS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application